

**Arecor Therapeutics plc**  
("Arecor" or the "Group")

**ARECOR GRANTED KEY PATENTS IN EUROPE AND CHINA TO PROTECT PROPRIETARY INSULIN PRODUCTS**

***Patents further strengthen Group's extensive patent portfolio protecting its Arestat™ technology and innovative insulin products, AT278 and AT247***

**Cambridge, UK, 27 June 2023:**Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, is pleased to announce that the European Patent Office has granted a key patent (EP3518892), protecting novel formulations of the Group's proprietary insulin products, AT278 and AT247. In addition, the China National Intellectual Property Administration has granted a further patent (CN110582285) protecting AT278 and AT247.

**Dr Jan Jezek, Chief Scientific Officer at Arecor, commented** *"Our innovative Arestat™ enabled insulin products, AT278 and AT247, have the potential to address key needs in the better treatment of diabetes. AT278 is a 'disrupter insulin', a unique formulation which combines an ultra-rapid profile and high concentration and has potential as the gold standard insulin for the growing population of people with high daily insulin needs, as well as a key enabler for pump miniaturisation and extended wear-time. AT247 has a 'best-in-class' ultra-rapid pharmacokinetic profile with the potential to enable fully automated insulin delivery systems. Diabetes is one of the leading causes of death and disability worldwide, and affects people regardless of country, age group, or sex. These additional granted patents aim to serve and protect Arecor's innovative technologies in these important markets."*

Arecor has invested in a strong patent portfolio to protect the Arestat™ technology platform and its proprietary pipeline products. The Group's intellectual property (IP) portfolio currently comprises 36 patent families, including >75 granted patents in Europe, the US and in other key territories, and provides protection for its key products. As part of this strategy, Arecor has robust IP that protects the novel compositions of AT278 and AT247 as well as their specific properties and methods of use until 2037.

AT278 is an ultra-concentrated (500 U/mL) novel formulation of insulin that has been designed to accelerate the absorption of insulin post injection, even when delivered at a high concentration. It has the potential to enable more effective management of blood glucose levels, especially in people with high daily insulin needs, whilst maintaining the convenience and compliance benefits that come from a lower injection volume via a single injection. Moreover, a truly rapid acting concentrated insulin is also a critical step towards developing the next generation of miniaturised insulin patch pumps, as well as pumps with longer wear-time and that can serve people with diabetes with a broader range of daily insulin needs.

AT247 is an ultra-rapid insulin that has been demonstrated in Phase I clinical studies to significantly accelerate insulin absorption. The faster absorption enables a more effective management of blood glucose levels for people living with diabetes, allowing for dosing closer to mealtimes. Faster acting insulins, in combination with state-of-the-art insulin pumps, glucose sensors and treatment algorithms are all necessary components of an 'artificial pancreas' designed to more closely mimic natural insulin function.

**-ENDS-**

**For more information, please contact:**

**Arecor Therapeutics plc**  
Dr Sarah Howell, Chief Executive Officer

[www.arecor.com](http://www.arecor.com)  
Tel: +44 (0) 1223 426060  
Email: [info@arecor.com](mailto:info@arecor.com)

Susan Lowther, Chief Financial Officer

Tel: +44 (0) 1223 426060

Josiah Lowther, Chief Financial Officer

Tel: +44 (0) 1223 420000

Email: [info@arecor.com](mailto:info@arecor.com)

Mo Noonan, Communications

Tel: +44 (0) 7876 444977

Email: [mo.noonan@arecor.com](mailto:mo.noonan@arecor.com)

**Panmure Gordon (UK) Limited** (NOMAD and Broker)  
Freddy Crossley, Emma Earl (Corporate Finance)  
Rupert Dearden (Corporate Broking)

Tel: +44 (0) 20 7886 2500

**Consilium Strategic Communications**  
Chris Gardner, David Daley, Angela Gray

Tel: +44 (0) 20 3709 5700

Email: [arecor@consilium-comms.com](mailto:arecor@consilium-comms.com)

## Notes to Editors

### About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.

For further details please see our website, [www.arecor.com](http://www.arecor.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCDBGDLBGDDGXL